The DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.
Lung cancer epigenetics: From knowledge to applications
Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide. Advances in our understanding of the genomics of lung cancer have led to substantial progress in the treatment of specific molecular subsets. Immunotherapy also emerges as a major breakthrough in lung cancer treatment. However, challenges remain as a consensual approach for early lung cancer detection remains elusive while primary or secondary drug resistance eventually leads to treatment failure in all patients with advanced disease. Furthermore, a large portion of patients are still treated with conventional chemotherapy that is only modestly effective. The last two decades have seen exponential developments in the epigenetic understanding of lung cancer. Epigenetic alterations in DNA methylation, non-coding RNA expression, chromatin modeling and post transcriptional regulators are key events in each step of lung cancer pathogenesis. Here, we review the central role epigenetic disruptions play in lung cancer carcinogenesis and the acquisition of cancerous phenotype and aggressive behavior as well as in the resistance to therapy. Epigenetic disruptions could represent reliable biomarkers for lung cancer risk assessment, early diagnosis, prognosis stratification, molecular classification and prediction of treatment efficacy. The therapeutic potential of epigenetics targeted drugs in combination with chemotherapy, targeted therapy and/or immunotherapy is currently being intensively investigated. We suggest that integration of tissue-derived or circulating epigenetic biomarkers and epidrugs in clinical trial design will translate epigenetic knowledge of lung cancer into the clinic and improve lung cancer patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–248 of 248
Lei, Z., Xu, G., Wang, L., Yang, H., Liu, X., Zhao, J., & Zhang, H. (2014) · The FASEB Journal · doi:10.1096/fj.13-247288 · Cited by 92
Kalari, S. K., Jung, M., Kernstine, K. H., Takahashi, T., & Pfeifer, G. P. (2012) · Oncogene · doi:10.1038/onc.2012.362 · Cited by 92
Hutt, J. A., Vuillemenot, B. R., Barr, E. B., Grimes, M. J., Hahn, F. F., HOBBS, C. H., March, T. H., Gigliotti, A. P., Seilkop, S. K., Finch, G. L., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi150 · Cited by 92
Epigenetic down-regulation of death-associated protein kinase in lung cancers.
Toyooka, S., Toyooka, K. O., Miyajima, K., Reddy, J., Toyota, M., Sathyanarayana, U. G., Padar, A., Tockman, M. S., Lam, S. C., Shivapurkar, N., et al. (2003) · PubMed · Cited by 89
Momparler, R. L., & Ayoub, J. (2001) · Lung Cancer · doi:10.1016/s0169-5002(01)00397-x · Cited by 89
Reguart, N., Rosell, R., Cardenal, F., Cardona, A. F., Isla, D., Palmero, R., Morán, T., Rolfo, C. D., Pallarès, M. C., Insa, A., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.02.011 · Cited by 89
Wrangle, J. M., Machida, E. O., Danilova, L., Hulbert, A., Franco, N. C., Zhang, W., Glöckner, S. C., Tessema, M., Neste, L. V., Easwaran, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2109 · Cited by 89
Hubaux, R., Thu, K. L., Coe, B. P., MacAulay, C. E., Lam, S. C., & Lam, W. L. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318298762f · Cited by 88
Kim, W., Holcomb, T., Januario, T., Du, P., Evangelista, M., Kartha, N., Iniguez, L. A., Soriano, R. H., Huw, L. Y., Stern, H. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2635-t · Cited by 86
Cost-Effectiveness of CT Screening in the National Lung Screening Trial
Pinsky, P. F. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1414726 · Cited by 85
Kim, J. S., Kim, J. W., Han, J., Shim, Y. M., Park, J., & Kim, D.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3813 · Cited by 84
SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway
Sun, Q., Ding, L., Xiao, J.-F., Chien, W., Lim, S. L., Hattori, N., Goodglick, L., Chia, D., Mah, V. H., Alavi, M., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4482 · Cited by 83
Nakata, S., Sugio, K., Uramoto, H., Oyama, T., Hanagiri, T., Morita, M., & Yasumoto, K. (2006) · Cancer · doi:10.1002/cncr.21870 · Cited by 82
Nishizaki, M., Sasaki, J.-I., Fang, B., Atkinson, E. N., Minna, J. D., Roth, J. A., & Ji, L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0195 · Cited by 80
Promoter Methylation of DAL-1/4.1B Predicts Poor Prognosis in Non–Small Cell Lung Cancer
Kikuchi, S., Yamada, D., Fukami, T., Masuda, M., Sakurai‐Yageta, M., Williams, Y. N., Maruyama, T., Asamura, H., Matsuno, Y., Onizuka, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2206 · Cited by 79
HDAC5 controls the functions of Foxp3+ T‐regulatory and CD8+ T cells
Xiao, H., Jiao, J., Wang, L., O’Brien, S., Newick, K., Wang, L. S., Falkensammer, E., Liu, Y., Han, R., Kapoor, V., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29979 · Cited by 77
Wang, G., Wang, R., Strulovici‐Barel, Y., Salit, J., Staudt, M. R., Ahmed, J., Tilley, A. E., Yee-Levin, J., Hollmann, C., Harvey, B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120824 · Cited by 76
Otterson, G. A., Hodgson, L. C., Pang, H., & Vokes, E. E. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ec1713 · Cited by 72
The relationship between aberrant methylation and survival in non-small-cell lung cancers
Toyooka, S., Suzuki, M., Maruyama, R., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602013 · Cited by 71
Sato, T., Arai, E., Kohno, T., Takahashi, Y., Miyata, S., Tsuta, K., WATANABE, S.-I. I., Soejima, K., Betsuyaku, T., & Kanai, Y. (2013) · International Journal of Cancer · doi:10.1002/ijc.28684 · Cited by 70
Dose effect of smoking on aberrant methylation in non‐small cell lung cancers
Toyooka, S., Suzuki, M., Tsuda, T., Toyooka, K. O., Maruyama, R., Tsukuda, K., Fukuyama, Y., Iizasa, T., Fujisawa, T., Shimizu, N., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20125 · Cited by 70
Seol, H. S., Akiyama, Y., Shimada, S., Lee, H. J., Kim, T. I., Chun, S., Singh, S. R., & Jang, S. J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.019 · Cited by 67
Shinjo, K., Okamoto, Y., An, B., Yokoyama, T., Takeuchi, I., Fujii, M., Osada, H., Usami, N., Hasegawa, Y., Ito, H. M., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs154 · Cited by 62
Nadal, E., Chen, G., Gallegos, M., Lin, L., Ferrer-Torres, D., Truini, A., Wang, Z., Lin, J., Reddy, R. M., Llatjós, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0736 · Cited by 62
Histone variant H3F3A promotes lung cancer cell migration through intronic regulation
Park, S., Choi, E.-Y., Bae, M., Kim, S., Park, J. B., Yoo, H., Choi, J. K., Kim, Y., Lee, S., & Kim, I.-H. (2016) · Nature Communications · doi:10.1038/ncomms12914 · Cited by 62
Fragile Histidine Triad Gene Inactivation in Lung Cancer: The European Early Lung Cancer Project
Verri, C., Roz, L., Conte, D., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200807-1153oc · Cited by 61
Wang, R., Shi, Y., Chen, L., Jiang, Y., Mao, C., Yan, B., Liu, S., Shan, B., Tao, Y., & Wang, X. (2015) · Scientific Reports · doi:10.1038/srep17826 · Cited by 59
New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer
Forde, P. M., Brahmer, J. R., & Kelly, R. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2088 · Cited by 57
Liu, M., Zhou, K., & Cao, Y. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-245 · Cited by 57
Sterlacci, W., Tzankov, A., Veits, L., Zelger, B. G., Bihl, M., Foerster, A., Augustin, F., Fiegl, M., & Savic, S. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182295745 · Cited by 55
Zhang, J., Feng, S., Su, W., Bai, S., Xiao, L., Wang, L., Thomas, D. G., Lin, J., Reddy, R. M., Carrott, P. W., et al. (2017) · Scientific Reports · doi:10.1038/srep42819 · Cited by 55
Fhit Regulates EMT Targets through an EGFR/Src/ERK/Slug Signaling Axis in Human Bronchial Cells
Joannes, A., Grelet, S., Duca, L., Gilles, C., Kileztky, C., Dalstein, V., Birembaut, P. L., Polette, M., & Nawrocki‐Raby, B. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0386-t · Cited by 53
Brahmer, J. R., Horn, L., Jackman, D. M., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct077 · Cited by 53
Hascher, A., Haase, A.-K., Hebestreit, K., Rohde, C., Klein, H., Rius, M., Jungen, D., Witten, A., Stoll, M., Schulze, I., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1483 · Cited by 48
Dasari, A. N., Gore, L., Messersmith, W. A., Diab, S., Jimeno, A., Weekes, C. D., Lewis, K. D., Drabkin, H. A., Flaig, T. W., & Camidge, D. R. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9812-z · Cited by 47
A high-throughput and sensitive method to measure Global DNA Methylation: Application in Lung Cancer
Anisowicz, A., Huang, H., Braunschweiger, K. I., Liu, Z., Giese, H., Wang, H., Mamaev, S. V., Olejnik, J., Massion, P. P., & Mastro, R. G. D. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-222 · Cited by 42
Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer
Teneng, I., Tellez, C. S., Picchi, M. A., Klinge, D. M., Yingling, C. M., Snider, A. M., Liu, Y., & Belinsky, S. A. (2014) · Oncogene · doi:10.1038/onc.2013.580 · Cited by 42
Epigenetic profiling joins personalized cancer medicine
Heyn, H., Méndez‐González, J., & Esteller, M. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.13.36 · Cited by 39
Self-citationPark, D. H., Jeon, H. S., LEE, S. Y., Choi, Y. Y., Lee, H. W., Yoon, S., LEE, J. C., YOON, Y. S., Kim, D. S., Na, M. J., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3111 · Cited by 39
miR-196b Is Epigenetically Silenced during the Premalignant Stage of Lung Carcinogenesis
Tellez, C. S., Juri, D. E., Do, K., Picchi, M. A., Wang, T. W., Liu, G., Spira, A. E., & Belinsky, S. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3367 · Cited by 37
Genome Wide Methylome Alterations in Lung Cancer
Mullapudi, N., Ye, B., Suzuki, M., Fazzari, M. J., Han, W., Shi, M. K., Marquardt, G., Lin, J., Wang, T., Keller, S. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143826 · Cited by 36
p16INK4a and beta-catenin alterations in rat liver tumors induced by NNK
Pulling, L. C. (2001) · Carcinogenesis · doi:10.1093/carcin/22.3.461 · Cited by 35
Gene Silencing Associated with SWI/SNF Complex Loss during NSCLC Development
Song, S., Walter, V., Karaca, M., Li, Y., Bartlett, C. S., Smiraglia, D. J., Serber, D., Sproul, C. D., Plass, C., Zhang, J., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0427 · Cited by 31
Yim, H. W., Slebos, R. J. C., Randell, S. H., Umbach, D. M., Parsons, A. M., Rivera, M. P., Detterbeck, F. C., & Taylor, J. A. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.01.023 · Cited by 30
Cheng, T., Hu, C., Yang, H., Cao, L., & An, J. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2623 · Cited by 27
Lenka, G., Tsai, M., Lin, H., Hsiao, J.-H., Lee, Y., Lu, T., Lee, J., Hsu, C., Lai, L., & Chuang, E. Y.-Y. (2017) · Scientific Reports · doi:10.1038/srep42573 · Cited by 27
Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer
O’Leary, K., Shia, A., Cavicchioli, F., Haley, V., Comino, A., Merlano, M. C., Mauri, F. A., Walter, K., Lackner, M. R., Wischnewsky, M. B., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.302 · Cited by 26
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line
Cavazzoni, A., Galetti, M., Fumarola, C., Alfieri, R. R., Roz, L., Andriani, F., Carbognani, P., Rusca, M., Sozzi, G., & Petronini, P. G. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.01.033 · Cited by 16
Cited by
Pyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Hoshino, A., Kim, H. S., Bojmar, L., Gyan, K. E., Cioffi, M., Hernandez, J., Zambirinis, C. P., Rodrigues, G., Molina, H., Heissel, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.009 · Cited by 1,242
Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression
Xue, C., Li, G., Lu, J., & Li, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00788-w · Cited by 268
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151
Bibaki, E., Tsitoura, E., Vasarmidi, E., Margaritopoulos, G., Trachalaki, A., Koutoulaki, C., Georgopoulou, T., Spandidos, D., Tzanakis, N., & Antoniou, K. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8778 · Cited by 29
Metadata
- Authors
- Duruisseaux, M., & Esteller, M.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 51
- Pages
- 116-128
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2754970987
- Cited by
- 283
- References
- 248
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
